Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Today's Featured Article Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably on edge after recent market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we're still in one of the best eras to build wealth—if you think long term and stick to time-tested principles. According to Green, this pullback isn't as severe as it may feel. "Just last Wednesday, the Dow hit an all-time high," he says, noting that recent selling pressure has more to do with valuation concerns and interest-rate uncertainty than any fundamental breakdown. Why the Market Pulled Back If your retirement strategy involves "picking the right stocks," you're one crash away from disaster…
A hedge fund legend who made $95 million in profits during a crash has a different way.
He's using 18-digit codes to "skim" the market without buying stocks.
And his followers have seen an 84%-win rate. Click here to see how he does it Green points to two core concerns. First, investors are reassessing elevated tech and AI valuations, and earnings season is putting those expectations under the microscope. Second, recent inflation readings and slower hiring have weakened hopes that the Fed will cut rates in December. With the central bank maintaining a "data-dependent" stance, markets are less certain relief is coming this year. Why Selling Now Might Be the Wrong Move Instead of trying to predict next week's moves, Green urges investors to zoom out. He describes himself as "a long-term optimist" and emphasizes that, historically, the market's long-term trend is upward. Traders may want to exercise short-term caution. But for long-term investors, market dips are often opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One useful indicator in choppy markets is insider buying. Green suggests paying attention when officers and directors—people with access to non-public financials—are putting money into their own companies. He recommends tracking insider trading activity to see which stocks executives are buying, not just selling. While insiders aren't always right, their actions can provide a helpful signal when markets are volatile. A Biotech Breakout to Watch: GRAIL One sector Green is watching closely is biotech, where artificial intelligence is accelerating drug development and reducing costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL developed the Galleri Test, which can detect more than 50 types of cancer from a simple blood draw. Green has used the test himself and says it gives "a good feeling" to know you're clear of so many deadly diseases—especially cancers like pancreatic that are often detected late. With FDA fast-track status and potential insurance reimbursement on the horizon, Green views GRAIL's roughly $3 billion market cap as a starting point. The Biotech Risk—and Big Pharma's Appetite Biotech investing carries substantial risk: most drug candidates never make it through all phases of clinical trials. Still, large pharmaceutical companies such as Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) actively acquire promising small caps to replenish pipelines as patents expire. Green points to Johnson & Johnson (NYSE: JNJ) as an example: the company invested in a private prostate-cancer drug candidate before FDA approval—illustrating how aggressive Big Pharma can be when clinical data looks promising. He also argues biotech is compelling now because healthcare is relatively recession-resistant. People seek medical treatment regardless of economic cycles, and sectors like healthcare, utilities, consumer staples, and food companies tend to offer steadier demand than high-flying AI names. The American Dream Is Still Possible—but Mindset Matters Despite economic challenges, Green contends the American Dream is far from dead. He wrote The American Dream to counter the narrative that it's out of reach, noting his surprise at polls showing nearly 70% of Americans believe it no longer exists. His message: with low-cost investment tools, commission-free trading, and abundant information, building wealth is more accessible than ever. The real challenge is knowing what to do—and having the discipline to follow through. He breaks it down simply: if a 25-year-old invests $190 per month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. "You could eat out, take trips, and still build wealth," Green says—as long as you save consistently and leave those investments to compound. Creative Solutions for Today's Housing Market Housing may feel out of reach, but Green says there are still paths in. Mortgage rates have risen and prices are higher than during the pandemic, but creative approaches can help prospective buyers get started. He shares his experience buying two houses with no money down by working directly with motivated sellers and assuming their mortgages—a method sometimes called a "contract for deed." It might not get you the perfect home immediately, but it can help you begin building equity sooner. Stay Focused on the Long Game Volatile markets come and go. What matters is how you respond. Whether it's tracking insider moves, exploring high-upside areas like biotech, or simply committing to a long-term savings plan, Green's message is clear: the American Dream is still within reach. You just have to keep your eyes on it—and take the next right step.
| 
